Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation

Objective: Tyloxapol is a non-ionic surfactant with diverse pharmacological effects including anti-inflammatory, anti-malignant tumor and antioxidant activities. However, the effect of tyloxapol on osteoclastogenesis has not been elucidated. In this study, we intended to clarify the effect of tyloxa...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Wen Guo, Haijun Li, Yan Lou, Yue Zhang, Jia Wang, Ming Qian, Haifeng Wei, Jianru Xiao, Youjia Xu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2021-05-01
Rangatū:	Journal of Orthopaedic Translation
Ngā marau:	Tyloxapol Osteoporosis Osteoclast Osteoblast Nuclear factor kappa-B (NF-κB) Mitogen-activated protein kinase (MAPK)
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2214031X21000061
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!